{"id":2703,"date":"2010-08-25T07:16:31","date_gmt":"2010-08-25T02:16:31","guid":{"rendered":"http:\/\/www.policymed.com\/cleveland-clinics-cosgrove-on-health-care-reform-and-innovation\/"},"modified":"2018-05-05T01:16:46","modified_gmt":"2018-05-04T20:16:46","slug":"cleveland-clinics-cosgrove-on-health-care-reform-and-innovation","status":"publish","type":"post","link":"https:\/\/www.policymed.com\/2010\/08\/cleveland-clinics-cosgrove-on-health-care-reform-and-innovation.html","title":{"rendered":"Cleveland Clinic\u2019s Cosgrove on Health Care Reform and Innovation"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">Cleveland Clinic Chief Executive Toby Cosgrove \u201ctold a full house at a City Club speech that he’s <\/span><\/span><a href=\"http:\/\/www.cleveland.com\/healthfit\/index.ssf\/2010\/08\/cleveland_clinic_ceo_toby_cosg.html\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"color: #800080; font-family: Arial;\">concerned<\/span><\/span><\/a><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\"> that health-care reform could stifle medical innovation.\u201d Specifically, he told more than 250 participants in response to a question that the effects of health-care reform are causing him to \u201cworry very significantly about innovation.” <\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">In particular, Cosgrove was pointing to the part of the health care law that funds comparative-effectiveness, which he asserted \u201cis shorthand for studying different treatments and paying for those that work.\u201d His concern about comparative-effectiveness is that it will create a system where \u201cwe only pay for one of those, and we begin to limit what people are willing to do in terms of developing new products.” <\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">To demonstrate his concern, he gave the example of how “right now, a new heart valve takes 10 years to go from concept to clinical. And it takes 10 years more to know if it’s better than the next heart valve.\u201d Using those numbers, he asked whether an investor or a manufacturer would be interested in essentially putting their dollars down not knowing whether they\u2019re going to get a return on those dollars for 20 years. And for most investors, \u201cthat\u2019s a stretch.\u201d <\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">As a result, he recognized the need for consumers and the public to watch how the regulations are written and implemented, and to keep an eye on how health care reform effects our exports, our employment, and one of our major industries in the United States: medical devices and drugs. <\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">While Cosgrove is still concerned about the effects this legislation will have, some feel that Congress \u201cand others are listening to the medical industry’s worries\u201d already. For<\/span> <span style=\"font-family: Arial;\">example, <span style=\"mso-spacerun: yes;\">\u00a0<\/span>Tom Hubbard, senior program director for the New England Healthcare Institute, noted that even the Institute of Medicine recognizes the need to protect innovation,” and that \u201cin general, nobody is against developing the next life-saving drug or the next life-saving device.” <\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">Others, such as David E. Williams, a health-care business consultant and principal at MedPharma Partners in Boston, don\u2019t \u201csee comparative effectiveness slowing innovation either.\u201d In fact, Williams sees comparative effectiveness “making it more likely that things that are truly innovative and will make it to market and it will discourage things that are flashy and expensive but don’t add much clinical value.” <\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">Despite their optimism, Cosgrove recognized in his speech that organizations and institutions must continue to be creative and to drive innovation. As a result, his comments correctly pointed out that in order to \u201censure our future success as a vibrant and growing international health-care delivery system, we must continue to put our patients first.\u201d<\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height: normal; margin: 0in 0in 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto;\"><span style=\"mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial;\"><span style=\"font-family: Arial;\">Accordingly, to carry out this mission, health care reform must not hinder health care providers and entities from taking risks with ideas, and collaborating with industry, government and academia to achieve the best results possible for patients.<\/span> <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cleveland Clinic Chief Executive Toby Cosgrove \u201ctold a full house at a City Club speech that he’s concerned that health-care reform could stifle medical innovation.\u201d Specifically, he told more than 250 participants in response to a question that the effects of health-care reform are causing him to \u201cworry very significantly about innovation.” In particular, Cosgrove […]<\/p>\n","protected":false},"author":1,"featured_media":4825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61,19],"tags":[1101],"class_list":["post-2703","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-reform","category-innovation","tag-new"],"_links":{"self":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/2703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/comments?post=2703"}],"version-history":[{"count":2,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/2703\/revisions"}],"predecessor-version":[{"id":4826,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/posts\/2703\/revisions\/4826"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media\/4825"}],"wp:attachment":[{"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/media?parent=2703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/categories?post=2703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.policymed.com\/wp-json\/wp\/v2\/tags?post=2703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}